Research and Development: Comparing Key Metrics for Exelixis, Inc. and Ultragenyx Pharmaceutical Inc.

Biotech R&D: A Decade of Growth and Innovation

__timestampExelixis, Inc.Ultragenyx Pharmaceutical Inc.
Wednesday, January 1, 201418910100045967000
Thursday, January 1, 201596351000114737000
Friday, January 1, 201695967000183204000
Sunday, January 1, 2017112171000231644000
Monday, January 1, 2018182257000293998000
Tuesday, January 1, 2019336964000357355000
Wednesday, January 1, 2020547851000412084000
Friday, January 1, 2021693716000497153000
Saturday, January 1, 2022891813000705789000
Sunday, January 1, 20231044071000648449000
Monday, January 1, 2024910408000
Loading chart...

Data in motion

A Decade of Innovation: R&D Spending in Biotech

In the competitive world of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Exelixis, Inc. and Ultragenyx Pharmaceutical Inc. have demonstrated significant investment in R&D, reflecting their dedication to advancing medical science.

Exelixis, Inc.: A Steady Climb

From 2014 to 2023, Exelixis, Inc. increased its R&D expenses by over 450%, showcasing a robust growth trajectory. This upward trend highlights the company's strategic focus on expanding its research capabilities and pipeline.

Ultragenyx Pharmaceutical Inc.: Consistent Growth

Ultragenyx Pharmaceutical Inc. also exhibited a strong commitment to R&D, with a 1,300% increase in spending from 2014 to 2022. Despite a slight dip in 2023, the company's overall trend underscores its persistent drive to innovate.

These trends underscore the dynamic nature of the biotech industry, where sustained R&D investment is key to long-term success.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025